HIV suppression with stavudine 30 mg versus 40 mg in adults over 60 kg on antiretroviral therapy in South Africa.
Hoffmann, Christopher J;
Charalambous, Salome;
Fielding, Katherine L;
Innes, Craig;
Chaisson, Richard E;
Grant, Alison D;
Churchyard, Gavin J;
(2009)
HIV suppression with stavudine 30 mg versus 40 mg in adults over 60 kg on antiretroviral therapy in South Africa.
AIDS (London, England), 23 (13).
pp. 1784-1786.
ISSN 0269-9370
DOI: https://doi.org/10.1097/QAD.0b013e32832e0585
Permanent Identifier
Use this Digital Object Identifier when citing or linking to this resource.
In 2007, the WHO recommended a maximum stavudine dose of 30 mg. We compared virologic suppression among patients weighing more than 60 kg and receiving stavudine 30 mg (n = 110) versus 40 mg (n = 508) in community HIV clinics in South Africa, before and after guidelines changed. At 6 months, HIV RNA less than 400 copies/ml was achieved in 79% and 81% receiving 30 and 40 mg stavudine, respectively (chi2, P = 0.6). In regression modeling, including baseline HIV RNA and nonnucleoside reverse transcriptase inhibitor agent, stavudine dose remained unassociated with suppression.
